|
FY2024
12 months to Mar 31, 2024
|
FY2023
12 months to Mar 31, 2023
|
FY2022
12 months to Mar 31, 2022
|
FY2021
12 months to Mar 31, 2021
|
FY2020
12 months to Mar 31, 2020
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Products | |||||
| Services | |||||
| Total Revenues | |||||
| Revenues | |||||
| Products | |||||
| Services | |||||
| Total revenues | |||||
| Cost of goods sold | |||||
| Products | |||||
| Services | |||||
| Total cost of goods sold | |||||
| Gross profit | |||||
| Gain on de-recognition of BESS project subsidiaries (Note 9) | |||||
| Interest income (expense) and other | |||||
| Expenses | |||||
| Advertising and promotion | |||||
| Amortization of intangible assets (Note 7) | |||||
| Bad debts expense (recovery) | |||||
| Depreciation (Note 6) | |||||
| Foreign exchange loss | |||||
| Impairment of goodwill (Note 8 and 9) | |||||
| Impairment of tangible assets | |||||
| Impairment of goodwill | |||||
| Impairment of tangible assets | |||||
| Loss on sale of PPE | |||||
| Impairment of intangible assets (Note 7) | |||||
| Management and technical consulting (Note 16) | |||||
| Operating lease expense (Note 20) | |||||
| Office and miscellaneous | |||||
| Professional fees | |||||
| Research and development | |||||
| Salaries and wage expense (Note 16) | |||||
| Salaries and wage expenses | |||||
| Transfer agent and filing fees | |||||
| Travel and accommodation | |||||
| Warranty and related | |||||
| Warranty and related expense (Note 14) | |||||
| Warranty (recovery) (Note 15) | |||||
| Total expenses | |||||
| Operating income (loss) | |||||
| Other income (expense) | |||||
| Interest Income (expense) | |||||
| Financing interest income | |||||
| Change in fair value of derivatives | |||||
| Loss on acquisition of subsidiary | |||||
| Interest income (expense) and other | |||||
| Total other (expense) income | |||||
| Income (loss) before income taxes | |||||
| Income tax charge (Note 21) | |||||
| Net income (loss) for the year | |||||
| Preference coupon distributions | |||||
| Share of (loss)/income attributable to NCI - BESS | |||||
| Share of (loss) income attributable to NCI - JV | |||||
| Net profit (loss) attributable to PGTK | |||||
| Foreign currency translation gain | |||||
| Other comprehensive income | |||||
| Foreign currency translation gain | |||||
| Comprehensive profit (loss) for the year | |||||
| Net profit (loss) per share, basic (in Dollars per share) | |||||
| Net profit (loss) per share, diluted (in Dollars per share) | |||||
| Weighted average number of shares outstanding, basic (in Shares) | |||||
| Weighted average number of shares outstanding, diluted (in Shares) | |||||
Loading...